IMRX

Immuneering is a pre-revenue, late-stage clinical oncology company whose entire equity value rests on one binary event: whether atebimetinib (IMM-1-104) works in the MAPKeeper 301 Phase 3 trial in first-line metastatic pancreatic cancer. The 10-K is explicit that IMRX 'has no products approved for commercial sale,' 'has not completed any registrational clinical trials,' and 'may never obtain profitability.' First-line PDAC is one of oncology's hardest graveyards, and even the encouraging January 2026 interim Phase 2a response/safety data is early and uncontrolled. For a disciplined retail investor, the forward outcome here is genuinely unknowable — that pushes it into 'avoid,' not because the balance sheet is weak, but because the payoff is bimodal (multi-bagger on success, near-zero on failure).

The financials are what you'd expect from a clinical biotech: zero product revenue (service revenue ceased in 2022), a FY2025 net loss of $56.0M, operating loss of $59.4M, and a -25.6% ROE against a $280M accumulated deficit. The one genuine positive is a fortress-clean balance sheet — $218M equity (up 428% YoY after capital raises), $129M cash, and just $13.5M total liabilities (0.06x liabilities/equity). But $45.3M annual operating cash burn against $129M cash is roughly ~2 years of runway BEFORE the cost step-up of a global 510-patient Phase 3, first patient dosed mid-2026. The MD&A confirms an active ATM program (5.16M shares sold at $3.03 in 2025) and share count already up 46.8% YoY, so meaningful further dilution to fund MAPKeeper 301 is close to certain.